Envista (NVST) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
28 Aug, 2026Executive summary
Achieved $731 million in Q2 2026 sales, with 5% core growth year-over-year and balanced contributions from both reporting segments and all major geographies.
Adjusted EBITDA increased 28% and adjusted EPS rose 58% year-over-year; free cash flow conversion was 158%.
Net income more than doubled year-over-year for the quarter ($53.7M vs. $26.4M), reflecting improved operating margins and tariff refunds.
Raised full-year 2026 guidance for core growth, adjusted EBITDA, and adjusted EPS.
2.4 million shares repurchased in Q2.
Financial highlights
Q2 2026 revenue was $731M, up 7.1% year-over-year; core sales up 5% year-over-year.
Adjusted gross margin was 55.1%, up 70 basis points; adjusted EBITDA margin at 14.7%, up 230 basis points.
Adjusted EPS was $0.41, up 58% year-over-year; GAAP diluted EPS was $0.33.
Free cash flow was $105M, a 38% increase year-over-year, including a $13M IEEPA tariff recovery.
Cash and cash equivalents totaled $1.13B at quarter-end.
Outlook and guidance
Full-year 2026 guidance: 3.5%-4.5% core growth, 11%-14% adjusted EBITDA growth, adjusted EPS of $1.50-$1.55, and ~100% free cash flow conversion.
Second half revenue growth expected to be lower due to billing day effects; Q4 core growth expected to be flat to slightly down.
Currency exchange rates and global economic conditions remain key variables for the remainder of the year.
Full-year tax rate expected at 26%, two points lower than initial guidance.
Latest events from Envista
- Dental markets recover, China VBP impacts short-term, but long-term growth outlook is positive.NVST
2026 Global Healthcare Conference - All proposals passed, directors elected, and no stockholder questions were raised.NVST
AGM 2026 - Q1 2026 saw strong sales, margin expansion, and a $300M buyback with guidance reaffirmed.NVST
Q1 2026 - Key votes include director elections, auditor ratification, and executive pay approval.NVST
Proxy filing - Annual meeting to vote on directors, auditor, executive pay, and ESG priorities.NVST
Proxy filing - Double-digit core sales, EBITDA, and EPS growth in 2025, with strong 2026 outlook.NVST
Q4 2025 - Q3 2025 delivered 9.4% core growth, 14.5% EBITDA margin, and raised full-year guidance.NVST
Q3 2025 - Q2 loss of $1.15B on impairments; sales and margins fell, but cash flow improved and Q4 growth is expected.NVST
Q2 2024 - Q4 core sales rose 2% with strong cash flow and a $250M share repurchase plan.NVST
Q4 2024